The 2009 Cumulative Supplement to Pharmaceutical Patent Law includes the following new information:
Legislative developments in the 111th Congress concerning patents, follow-on biologics, and Hatch-Waxman reform
The continuing impact of Supreme Court precedent upon pharmaceutical patent law, including the law of obviousness and declaratory judgment jurisdiction
The new rules concerning the extension of the Hatch-Waxman Act's 30-month stay of marketing approval
Coverage of judicial reaction to concerns over baseless paragraph IV ANDA filings
Updated information on the construction of pharmaceutical patent claims
Another publisher created this product. Why should I buy it from the ABA?
We want the ABA Web store to carry any title that is useful to practicing lawyers and judges. So in addition to the hundreds of products published by the ABA itself, the Web store now offers hundreds of titles from other publishers, including BNA, Oxford University Press, Harvard Business School Press, Wiley, Merriam-Webster, and many others.
The ABA has entered into a distribution arrangement with these other publishers, and receives a small discount on the list price of each book it resells. When you buy these products from the ABA rather than direct from the publisher or from another online retailer, you directly support the many programs and initiatives of the ABA.
To Order the Package
For information on the Main Volume and 2009 Cumulative Supplement together, click here.
